Institutional Fund
Caxton Corp
Princeton, NJCIK 13885515 filings on record
Portfolio Value
$4.02M
Q1 2026
Holdings
7
Reported positions
New Buys
1
Opened this quarter
QoQ Change
-6.0%
from $4.28M
Portfolio Value Trend
Reported 13F value by quarter
Portfolio value trend — upgrade to see history
UpgradeTop Allocations
Largest positions by weight
- Spdr Gold Tr81.5%
- Berkshire Hathaway Inc Del8.7%
- Kyverna Therapeutics Inc4.0%
- Lexeo Therapeutics Inc2.0%
- X4 Pharmaceuticals Inc1.6%
- Inhibikase Therapeutics Inc1.2%
- Other1.0%
Portfolio Holdings
7 positions · Q1 2026
| # | Security | Shares | Value | % Port. | Δ Shares | Activity |
|---|---|---|---|---|---|---|
| 1 | Spdr Gold Tr | 7.6K | $3.28M | 81.5% | +659 | Added |
| 2 | Berkshire Hathaway Inc Del | 727 | $348.3K | 8.7% | +17 | Added |
| 3 | Kyverna Therapeutics Inc | 18.8K | $162.0K | 4.0% | 0 | Held |
| 4 | Lexeo Therapeutics Inc | 13.9K | $80.0K | 2.0% | 0 | Held |
| 5 | X4 Pharmaceuticals Inc | 15.6K | $64.2K | 1.6% | 0 | Held |
| 6 | Inhibikase Therapeutics Inc | 28.5K | $47.8K | 1.2% | 0 | Held |
| 7 | Alx Oncology Hldgs Inc | 20.9K | $42.0K | 1.0% | +20.9K | New |